Y. Kim

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

J. Dancey, F. Shepherd, R. Ramlau, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)

F. Fossella, M. Millward, J. Bérille, 2000 .

Phase II study of weekly docetaxel in patients with metastatic breast cancer.

T. Aihara, Y. Takatsuka, Y. Kim, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.

B. Cho, E. Shin, S. Park, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer].

Y. Takatsuka, Y. Kim, N. Aritake, 1999, Gan to kagaku ryoho. Cancer & chemotherapy.

Prospective R andomized T rial o f D ocetaxel V ersus B est Supportive C are i n P atients W ith N on-Small-Cell L ung Cancer P reviously T reated W ith P latinum-Based Chemotherapy

J. Dancey, F. Shepherd, R. Ramlau, 2011 .

Randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy

F. Shepherd, R. Ramlau, R. Gralla, 1999 .

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.

B. Cho, H. Shim, E. Shin, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective randomized trial of Taxotere versus best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy: Survival update

J. Dancey, F. Shepherd, R. Ramlau, 2000 .

Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)

A. Drilon, J. Wolf, B. Besse, 2020, Pneumologie.